Abstract
Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are concomitant diseases that are based on common pathogenetic mechanisms and have negative impact on the each other severity. A modern strategy in the severe asthma and CRSwNP treatment is the use of biologicals – monoclonal antibodies that block various pathways of the T2-inflammation, which underlies the development of these diseases. Despite the fact that biologicals used in the asthma and CRSwNP treatment are highly effective and safe, they are not universal and have some limitations associated with their action mechanism. Hence, the biologicals selection should be personalized, taking into account all the patient’s phenotypic and endotypic characteristics. Moreover, an important condition for the effective and safe therapy with biologicals is dynamic observation with regular clinical and laboratory asessments. The importance of these aspects was shown by a clinical case.
Key words: asthma, chronic rhinosinusitis with nasal polyps, biologicals, biologics, monoclonal antibodies, dupilumab, mepolizumab, peripheral blood eosinophilia, hypereosiniphilia.
Key words: asthma, chronic rhinosinusitis with nasal polyps, biologicals, biologics, monoclonal antibodies, dupilumab, mepolizumab, peripheral blood eosinophilia, hypereosiniphilia.
For citation:Pavlova K.S., Timoshenko D.O., Rodionova M.A. et al. Personalized approach to the biologicals selection and therapy in patients with asthma and chronic rhinosinusitis with nasal polyps: clinical case analysis. Clinical review for general practice. 2023; 4 (8): 24–28 (In Russ.). DOI: 10.47407/kr2023.4.8.00327
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
